Stocks Slip as Pand...
Health Care: Drugs
Dyax Corporation (DYAX: NASDAQ)
$2.60 -0.02 | -0.76%
05/24/13 - 02:48 PM ET
Company Income Statement
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Sales | 54.65M | 48.74M | 51.40M | 21.64M |
| Cost of Sales | 1.03M | 1.22M | 505.00K | -2.79M |
| Gross Operating Profit | 53.62M | 47.51M | 50.89M | 24.43M |
| Selling, General, and Administrative Expenses | 39.92M | 37.74M | 33.58M | 25.84M |
| Research & Development | 30.03M | 34.68M | 31.52M | 46.59M |
| Operating Income before D & A (EBITDA) | -16.32M | -24.90M | -14.21M | -48.00M |
| Depreciation & Amortization | 1.12M | 1.65M | 1.56M | 2.79M |
| Interest Income | 111.00K | 554.00K | 1.64M | 1.74M |
| Other Income - Net | 0.00 | 0.00 | 0.00 | 0.00 |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | -955.00K |
| Total Income Before Interest Expenses (EBIT) | -18.77M | -25.99M | -14.13M | -52.34M |
| Interest Expense | 10.49M | 10.25M | 11.94M | 10.08M |
| Pre-Tax Income | -29.26M | -36.24M | -26.06M | -62.42M |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -29.26M | -34.60M | -24.50M | -62.42M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -29.26M | -34.60M | -24.50M | -62.42M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -29.26M | -34.60M | -24.50M | -62.42M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-27.82M | -34.60M | -24.50M | -59.13M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -29.26M | -34.60M | -24.50M | -62.42M |
| Basic EPS from Continuing Ops. | -0.30 | -0.35 | -0.26 | -0.90 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.30 | -0.35 | -0.26 | -0.90 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.30 | -0.35 | -0.26 | -0.90 |
| Basic Normalized Net Income/Share | -0.29 | -0.35 | -0.26 | -0.85 |
| EPS fr Continuing Ops. | -0.30 | -0.35 | -0.26 | -0.90 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.30 | -0.35 | -0.26 | -0.90 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.30 | -0.35 | -0.26 | -0.90 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.29 | -0.35 | -0.26 | -0.85 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with DYAX
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
- UserSUPRATRADE-0303071618
- Userdulcinea
- ContributorOptions Action Portfolio Fe...
- UserLast Day of the JPMorgan He...
- UserBarron's Research Reports 7...
- UserPART 6 JPMorgan 26th Annual...
- Userpnp.v
- UserSpec #1
- Userjan's specs
Latest DYAX Headlines from TheStreet
- 5 Biotech Stocks Poised for Breakouts 07.27.12 | 01:07 pm
- Dyax Corporation CEO Discusses Q2 2012 Results - Earnings Call Transcript 07.19.12 | 08:07 pm
- Dyax's CEO Presents At Deutsche Bank AG Health Care Conference (Transcript) 05.07.12 | 03:05 pm
- Dyax Stock Gaps Down On Today's Open (DYAX) 07.19.11 | 09:07 am
- Dyax Corporation CEO Discusses Q3 2010 Results - Earnings Call Transcript 10.28.10 | 03:10 am
- Dyax Corp. Q2 2010 Earnings Call Transcript 07.28.10 | 10:07 pm
- Merck Buys British Maker Of Biotech Medicines 12.17.09 | 12:12 pm
- Cubist Stops Enrollment In Anti-bleeding Studies 12.03.09 | 01:12 pm
- Delta, Walgreen, Diedrich Coffee Are Big Movers 12.02.09 | 04:12 pm
- Dyax Shares Rocket On FDA Clearance For Kalbitor 12.02.09 | 11:12 am
Press Releases for DYAX
- Dyax Corp. To Participate In The 25th Annual ROTH Conference - Business Wire 03.12.13 | 07:03 am
- Dyax Announces Management Change - Business Wire 03.08.13 | 08:03 am
- Dyax Presents DX-2930 Data At The 2013 American Academy Of Allergy, Asthma And Immunology Annual Meeting - Business Wire 02.25.13 | 07:02 am
- Dyax Corp. To Participate In Upcoming 2013 Healthcare Conferences - Business Wire 02.20.13 | 07:02 am
- Dyax Corp. Announces Fourth Quarter And Full Year 2012 Financial Results - Business Wire 02.13.13 | 04:02 pm
- Dyax Corp. And CVie Therapeutics Announce Partnership To Develop And Commercialize KALBITOR® (ecallantide) For Hereditary Angioedema (HAE) And Other Angioedema Indications In China, Hong Kong And Macau - Business Wire 02.07.13 | 07:02 am
- Dyax Corp. To Participate In The Leerink Swann Global Healthcare Conference - Business Wire 02.06.13 | 07:02 am
- Dyax Corp. To Host Fourth Quarter And Year End 2012 Earnings Call And Webcast - Business Wire 02.05.13 | 07:02 am
- Dyax Corp. And Novellus Biopharma AG Announce Partnership To Develop And Commercialize KALBITOR® (ecallantide) For Hereditary Angioedema (HAE) And Other Angioedema Indications In Latin America - Business Wire 01.31.13 | 07:01 am
- Behind The Success - Research Report On Corcept Therapeutics Inc. And Dyax Corp. - PR Newswire 01.23.13 | 08:01 am
Partner Headlines for DYAX
- Microvision CRASHES 24% to Lead 3 NASDAQ Top Percentage Losers - Wall St. Cheat Sheet 06.18.12 | 09:06 am
- Barclays UPGRADES Dollar General to Overweight and 4 Stocks on Analyst Radars - Wall St. Cheat Sheet 06.15.12 | 04:06 am
- Morning Market Losers - Benzinga 07.19.11 | 09:07 am
- Zacks #5 Rank Additions for Wednesday - Tale of the Tape - Zacks 07.13.11 | 09:07 am
- Low-Priced Biotech Stocks With Insider Buying - Seeking Alpha 03.18.11 | 06:03 pm
- Dyax Corp. Hits New 52-Week Low (DYAX) - Benzinga 01.04.11 | 09:01 am
- UPDATE 1-Dyax, Sigma-Tau agree to develop, market genetic drug - Reuters 06.21.10 | 08:06 am
- CORRECTED - CORRECTED-UPDATE 1-Dyax posts narrower-than-expected Q4 loss - Reuters 02.17.10 | 09:02 am
